Evidence map›Paper›PMID 36319844›Full record

Observational studyScientific reports2022

Discovery of four plasmatic biomarkers potentially predicting cardiovascular outcome in peripheral artery disease.

B M M Kremers, J N Posma, S Heitmeier, J Glunz, H Ten Cate, A Pallares Robles, J H C Daemen, A J Ten Cate-Hoek, B M E Mees, H M H Spronk

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. The role of IL-6 in atherosclerosis: a narrative review.Frontiers in cardiovascular medicine · 2026
    Review
  5. Review
  6. Nicotine Potentially Alters Endothelial Inflammation and Cell Adhesion viaJournal of cardiovascular development and disease · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

B M M KremersLaboratory for Clinical Thrombosis and Hemostasis, Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Universiteitssingel 50, Room 4.330, 6229 ER, Maastricht, The Netherlands. b.kremers@student.maastrichtuniversity.nl.
J N PosmaLaboratory for Clinical Thrombosis and Hemostasis, Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Universiteitssingel 50, Room 4.330, 6229 ER, Maastricht, The Netherlands.
S HeitmeierBayer AG, Wuppertal, Germany.
J GlunzBayer AG, Wuppertal, Germany.
H Ten CateLaboratory for Clinical Thrombosis and Hemostasis, Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Universiteitssingel 50, Room 4.330, 6229 ER, Maastricht, The Netherlands.
A Pallares RoblesCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
J H C DaemenDepartment of Vascular Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
A J Ten Cate-HoekLaboratory for Clinical Thrombosis and Hemostasis, Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Universiteitssingel 50, Room 4.330, 6229 ER, Maastricht, The Netherlands.
B M E MeesDepartment of Vascular Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
H M H SpronkLaboratory for Clinical Thrombosis and Hemostasis, Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Universiteitssingel 50, Room 4.330, 6229 ER, Maastricht, The Netherlands.
Maastricht University · NLBayer (Germany) · DEJohannes Gutenberg University Mainz · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DE

Funding

European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie agreement 813409
6 · The paper itself

Abstract

Peripheral artery disease (PAD) patients have an increased cardiovascular risk despite pharmacological treatment strategies. Biomarker research improving risk stratification only focused on known atherothrombotic pathways, but unexplored pathways might play more important roles. To explore the association between a broad cardiovascular biomarker set and cardiovascular risk in PAD. 120 PAD outpatients were enrolled in this observational cohort study. Patients were followed for one year in which the composite endpoint (myocardial infarction, coronary revascularization, stroke, acute limb ischemia and mortality) was assessed. Patient data and blood samples were collected upon inclusion, and citrated platelet-poor plasma was used to analyze 184 biomarkers in Olink Cardiovascular panel II and III using a proximity extension assay. Fifteen patients reached the composite endpoint. These patients had more prior strokes and higher serum creatinine levels. Multivariate analysis revealed increased plasma levels of protease-activated receptor 1 (PAR1), galectin-9 (Gal-9), tumor necrosis factor receptor superfamily member 11A (TNFRSF11A) and interleukin 6 (IL-6) to be most predictive for cardiovascular events and mortality. Positive regulation of acute inflammatory responses and leukocyte chemotaxis were identified as involved biological processes. This study identified IL-6, PAR1, Gal-9, TNFRSF11A as potent predictors for cardiovascular events and mortality in PAD, and potential drug development targets.

Indexed as

Peripheral Arterial DiseaseStrokeBiomarkersHumansInterleukin-6Receptor, PAR-1Risk FactorsTreatment OutcomeBiomarkersInterleukin-6Receptor, PAR-1

Identifiers

PMID36319844
PMCPMC9626632
OpenAlexW4308025750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.